Qualigen Therapeutics (NASDAQ:AIXC) Stock Price Up 2.3% – What’s Next?

Qualigen Therapeutics, Inc. (NASDAQ:AIXC)’s stock price traded up 2.3% during trading on Monday . The stock traded as high as $1.32 and last traded at $1.31. 28,151 shares were traded during trading, a decline of 41% from the average session volume of 47,878 shares. The stock had previously closed at $1.28.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Qualigen Therapeutics in a report on Friday, April 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Qualigen Therapeutics Trading Up 2.3%

The stock has a market cap of $26.51 million, a P/E ratio of -0.20 and a beta of 0.50. The company has a 50-day moving average of $1.33.

Qualigen Therapeutics (NASDAQ:AIXC) last issued its earnings results on Tuesday, May 12th. The company reported ($0.79) EPS for the quarter.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.